All In Biotech

Drug Trial Radar · NCT06671392

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

A Multi-center, Randomized, Double-blind, Parallel Design, Phase III Study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients With Essential Hypertension Inadequately Controlled With DWC202405

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Feb 24, 2025

Primary completion

Feb 5, 2026

Study completion Feb 5, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405

Conditions

  • Essential Hypertension

Interventions

  • DWC202405Drug

    5/20mg, 1 tablet, Oral, Once a day

  • DWC202405, DWC202314Drug

    5/20mg + 1.5mg, 1 tablet, Oral, Once a day

  • DWC202405, DWC202314PDrug

    5/20mg + 1.5mg, 1 tablet, Oral, Once a day

  • DWC202313, DWC202314Drug

    10/40mg + 1.5mg, 1 tablet, Oral, Once a day

  • DWC202313, DWC202314PDrug

    10/40mg + 1.5mg, 1 tablet, Oral, Once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baselineTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University ANAM Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.